ADC Therapeutics SA (ADCT)
| Market Cap | 190.22M -58.9% |
| Revenue (ttm) | 79.58M +3.0% |
| Net Income | -96.91M |
| EPS | -0.65 |
| Shares Out | 127.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,331,061 |
| Open | 1.470 |
| Previous Close | 1.450 |
| Day's Range | 1.460 - 1.565 |
| 52-Week Range | 0.780 - 4.980 |
| Beta | 1.86 |
| Analysts | Buy |
| Price Target | 3.33 (+123.49%) |
| Est. Earnings | Nov 9, 2026 |
About ADCT
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue... [Read more]
Financial Performance
In 2025, ADC Therapeutics's revenue was $81.36 million, an increase of 14.85% compared to the previous year's $70.84 million. Losses were -$142.62 million, -9.64% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for ADCT stock is "Buy." The 12-month stock price target is $3.33, which is an increase of 123.49% from the latest price.
News
ADC Therapeutics announces comprehensive strategic financial restructuring
ADC Therapeutics (ADCT) announced a comprehensive strategic financial restructuring designed to strengthen its balance sheet, reduce leverage, increase strategic optionality and extend cash runway int...
ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
$86.6 Million Private Placement announced, with participation from new and existing investors, extending expected cash runway into 2029 HealthCare Royalty financing agreement amended, removing change...
These beaten-down stocks could bounce back in January, if history is any guide
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
ADC Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
ZYNLONTA demonstrates strong efficacy and safety in DLBCL and marginal zone lymphoma, with promising results from combination studies and ongoing regulatory engagement. Key upcoming milestones include ASH data releases and a robust cash position supports continued development.
ADC Therapeutics Slides: 12th Annual Cantor Fitzgerald Global Healthcare Conference
ADC Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 11, 2026.
ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
LAUSANNE, Switzerland, Sept. 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2026 Cantor...
ADC Therapeutics price target lowered to $5 from $10 at Guggenheim
Guggenheim analyst Michael Schmidt lowered the firm’s price target on ADC Therapeutics (ADCT) to $5 from $10 and keeps a Buy rating on the shares. ADC Therapeutics faces increased regulatory…
ADC Therapeutics reports Q2 adjusted EPS (11c) vs. (25c) last year
Reports Q2 revenue $18.6M, consensus $18.9M. “We are pleased by our Q2 performance, which reflects continued commercial momentum and strong operational discipline through ongoing cost reduction effort...
ADC Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 saw stable ZYNLONTA revenues and reduced operating expenses, with a strong cash position supporting operations into 2028. Regulatory uncertainty surrounds LOTIS-5, but promising LOTIS-7 data and cost-saving measures position the company for future growth.
ADC Therapeutics Earnings release: Q2 2026
ADC Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
ADC Therapeutics Slides: Q2 2026
ADC Therapeutics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
ADC Therapeutics Quarterly report: Q2 2026
ADC Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
ADC Therapeutics Slides: Corporate presentation
ADC Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026 LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASH Company ev...
ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
LAUSANNE, Switzerland, Aug. 6, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
ADC Therapeutics Announces New Employee Inducement Grant
LAUSANNE, Switzerland, July 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
ADC Therapeutics completes enrollment in Phase 1b Zynlonta trial
ADC Therapeutics (ADCT) announced the completion of enrollment in the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of Zynlonta in combination with the bispecific antib...
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamab Full data expected in fourth quarter of 2026 LAUSANNE, Switzerland, June 30, 2026 /PRNewswire/ -- ADC Therape...
ADC Therapeutics to reduce workforce by 17% globally
ADC Therapeutics (ADCT) announced a strategic reorganization to focus resources behind key value-driving initiatives in support of the ZYNLONTA, or loncastuximab tesirine-lpyl, franchise. As part of t...
ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
Planned ~17% workforce reduction expected to generate annualized estimated savings of approximately $10M, enhancing financial flexibility Company focused on delivering upcoming regulatory and clinical...
ADC Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded ADC Therapeutics (ADCT) to Neutral from Buy without a price target The firm says the LOTIS-5 trial calls Zynlonta’s risk-benefit profile into question. The firm sees a…
ADC Therapeutics price target lowered to $5 from $8 at Stephens
Stephens analyst Sudan Loganathan lowered the firm’s price target on ADC Therapeutics (ADCT) to $5 from $8 and keeps an Overweight rating on the shares after LOTIS-5 top line data…
ADC Therapeutics plunges after patient deaths in blood cancer drug trial
ADC Therapeutics shares slumped nearly 53% in premarket trading on Thursday after a late-stage study testing its blood cancer drug showed more deaths among treated patients, despite meeting its main ...
ADC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded ADC Therapeutics (ADCT) to Sector Perform from Outperform with a price target of $2, down from $6, after the company announced results from their LOTIS-5 trial in…
ADC Therapeutics Transcript: Study result
The phase III LOTIS-5 trial in 2L+ DLBCL met its primary endpoint, showing improved PFS and higher CR rates for ZYNLONTA plus rituximab versus R-GemOx, with manageable but increased Grade 5 adverse events in elderly patients. Regulatory submission is planned for late 2026.